Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM).


Nakamura I(1), Maegawa H(2), Tobe K(3), Uno S(4).
Author information:
(1)Operational Excellence, Medical Affairs Japan, Astellas Pharma Inc ., Tokyo, Japan.
(2)Department of Medicine, Shiga University of Medical Science , Shiga, Japan.
(3)First Department of Internal Medicine, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama , Toyama, Japan.
(4)Data Science, Development, Astellas Pharma Inc ., Tokyo, Japan.


Erratum in Expert Opin Pharmacother. 2021 Jul;22(10):i.